Last reviewed · How we verify

NCT05311137: CONTROL-AF

Study of the Closed-loop Treatment Concept of Atrial Fibrillation in the Atrial Fibrillation Population

Recruiting now Last updated 24 May 2022
What this trial tests

trial testing Radiofrequency ablation in Atrial Fibrillation in 5,000 participants. Currently enrolling.

Timeline
1 May 2022
Primary endpoint
1 January 2024
1 January 2032

Quick facts

Lead sponsorShanghai 10th People's Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment5,000
Start date1 May 2022
Primary completion1 January 2024
Estimated completion1 January 2032
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

Adults 18 to 100, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the concept of closed-loop treatment of atrial fibrillation for the optimization of the treatment strategy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Radiofrequency ablation

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05311137.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing